Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to describe the hormones controlling fluid balance in pediatric patients with nephrotic syndrome. Further more, an analysis of the urinary and plasma proteins will be done using proteomics. Different composition of proteins in the urine or plasma might indicate if the patients will respond to treatment or not.


Clinical Trial Description

Nephrotic syndrome represents the association of proteinuria, hypoalbuminemia, oedema and hyperlipidemia. The pathogenesis of the oedemas remains controversial. The "underfill" theory is the traditional explanation where massive proteinuria leads to low plasma albumine and a subsequent decrease in intravascular osmotic pressure leading to edema formations. Because most patients are normotensive and have normal intravascular pressure the "overfill" theory has been proposed suggesting a primary defect in renal sodium handling being responsible for oedema formation.

Ten percent of the children with nephrotic syndrome do not respond to standard steroid treatment and a significant proportion of these patients progress towards end-stage renal failure. At initial presentation it cannot be said if a patient will respond to treatment or not.

The purposes of the sudy:

1. To describe changes in the hormones, Aldosterone, Atrial Natriuretic Peptide (ANP), Arginin Vasopressin (AVP), Renin and Angiotensin II in patients with idiopathic nephrotic syndrome and to analyse to what extend the change in these hormones reflected a "underfill" or "overfill" situation.

2. To describe changes in the urine concentration of the water channel AQP II and the sodium channel ENaC during the course of nephrotic syndrome.

3. To test the hypothesis that urine and plasma proteomics from patients with steroid resistant nephrotic syndrome differs from patients with steroid sensitive nephrotic syndrome.

50 pediatric patients with nephrotic syndrome will be included after informed consent from both parents.

At day 1, 2, 3, 30 and 120 blood samples for hormones will be taken together with creatinin, albumine, Na+, K+, Hgb. An Echocardiography will be performed at day 1 and day 30 to determine v. cava inferior index.

At day 1,30 and 120 urine and plasma will be collected for proteomics and measurement of AQP II and ENaC concentrations.

Further more a clinical examination will be performed at day 1, 2, 3, 30 and 120 and weight, blood pressure and response to treatment will be recorded. ;


Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00690586
Study type Observational
Source Aarhus University Hospital
Contact
Status Completed
Phase N/A
Start date December 2007
Completion date May 2010

See also
  Status Clinical Trial Phase
Completed NCT02238418 - Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. Phase 4
Completed NCT01895894 - Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome Phase 4
Completed NCT01411982 - Role of PACAP in Nehprotic Syndrome N/A
Recruiting NCT00308321 - Long Term Tapering or Standard Steroids for Nephrotic Syndrome Phase 4
Active, not recruiting NCT03326037 - Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East
Recruiting NCT01240564 - The Nephrotic Syndrome Study Network (NEPTUNE) N/A
Completed NCT01252901 - Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases N/A
Completed NCT01197040 - Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome Phase 3
Terminated NCT00883636 - Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis N/A
Completed NCT00035334 - Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis Phase 2/Phase 3
Terminated NCT00004466 - Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome Phase 2
Terminated NCT04558892 - Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome. Phase 2/Phase 3
Completed NCT02257697 - A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome Phase 3
Completed NCT00362531 - Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Phase 2/Phase 3
Completed NCT00289328 - Glucocorticoid-induced Osteopenia in Children N/A
Recruiting NCT04759274 - Diuretic Tuner Clinical Decision Support N/A
Completed NCT00001212 - Drug Therapy in Lupus Nephropathy Phase 2
Recruiting NCT05623033 - The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection
Completed NCT03332420 - The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
Not yet recruiting NCT05904197 - Effectiveness of Educational Gamified Cards About Nephrotic Syndrome N/A